Objectives-Hysterosalpingo-foam sonography (HyFoSy) has been suggested to be a possible less invasive alternative to hysterosalpingography (HSG), which is the reference standard for confirmation of tubal occlusion after Essure (Bayer AG, Leverkusen, Germany) hysteroscopic sterilization. The purpose of our study was to evaluate the accuracy of HyFoSy compared to HSG for confirmation of tubal occlusion after Essure hysteroscopic sterilization.
lumen is occluded by a benign tissue ingrowth stimulated by the polyethylene terephthalate fibers. 3 Three months after the procedure, a confirmation test is performed to evaluate tubal occlusion or the microinsert position. 5 During this period, the use of additional contraceptives is recommended until the correct microinsert position or bilateral tubal occlusion is confirmed. 6 A proper interpretation of the confirmation test is crucial because a misinterpretation could result in unwanted pregnancies. 7 The imaging techniques used for ascertaining the correct microinsert position or tubal occlusion may vary among countries 8 and include hysterosalpingography (HSG), 7 sonography, 4, [8] [9] [10] [11] plain pelvic radiography, 8 and hysterosonography. [12] [13] [14] However, HSG remains reference standard. 8, 12, 13 Non-HSG techniques are preferred because HSG is an invasive procedure that exposes the patient to ionizing radiation, 12 is uncomfortable for the patient, and can be associated with pelvic infections, vasovagal reactions, anaphylactic shock, uterine bleeding, or uterine perforation. 13 Hysterosalpingo-foam sonography (HyFoSy) is a possible alternative to HSG. This less invasive sonographic tubal patency test was introduced in 2011. 15 It can be performed by a single operator in an outpatient setting without the need for radiation exposure. Recent studies indicate that HyFoSy is a safe, 16 quicker, and less painful procedure; therefore, it is considered more patient friendly compared to HSG. 17 It has been suggested to be an accurate test for showing tubal patency in subfertile patients 16, 18, 19 and tubal occlusion in patients treated with Essure micro inserts for hydrosalpinges before in vitro fertilization. 17, 20 The objective of our study was to evaluate the accuracy of HyFoSy as a confirmation test for patients after Essure hysteroscopic sterilization.
Materials and Methods
After the approval of the National Medical Ethics Committee, a total of 90 patients were enrolled in a prospective nonrandomized, single-center study (clinical trial registration number ISRCTN13414740). Written consent was obtained from all patients. All procedures were performed at the University Medical Center Maribor. Our primary outcome was the accuracy of HyFoSy compared to HSG for confirmation of tubal occlusion after Essure hysteroscopic sterilization. The secondary outcome was to evaluate the correlation between 2-dimensional (2D) transvaginal ultrasonography (TVU) of the microinsert position and proximal tubal occlusion on HSG.
Essure hysteroscopic sterilizations were performed between January 2013 and June 2016 by the same experienced hysteroscopist in an outpatient setting. The procedures were scheduled in the proliferative phase of the menstrual cycle or shortly after withdrawal bleeding if patients were using oral contraceptives. Patients were informed about the possible complications. One hour before the procedure, the patients received premedication with 5 mg of diazepam orally and 100 mg of ketoprofen rectally. During the procedure, a 5.5-mm continuous-flow rigid hysteroscope with a 30 8 lens and a 5F working channel was introduced into the uterine cavity by a vaginoscopic approach. Saline solution was used to distend the uterus, while Essure microinserts were placed into the proximal portion of the fallopian tubes as described in the product literature. After the procedure, the patients were instructed to continue using an alternative method of contraception until the confirmation tests were performed 3 months after the procedure. All patients were scheduled for a 12-week follow-up, which included 2D TVU, HyFoSy, and HSG. During HyFoSy and HSG, they were asked to assess their pain on a 0-to-10 visual analog scale, where 0 was the absence of pain, and 10 was the worst pain imaginable.
Two-dimensional TVU was performed by a single sonographer with 15 years of experience to assess the microinsert position with a SonoAce X6 ultrasound system (Samsung Medison, Seoul, Korea). The position of the microinserts was defined as satisfactory when there was an appropriate intramural position of the insert at the tubocornual junction of the uterus ( Figure 1 ) and unsatisfactory when it was in a position other than the tubocornual junction or the examination was uninterpretable.
To verify tubal occlusion, HyFoSy was performed by the same sonographer in the same setting. During the procedure, a cervical balloonless catheter was placed into the cervix, through which 20 mL of foam was infused into the uterine cavity. The foam was created by mixing 10 mL of ExEm gel with 10 mL of purified water (ExEm foam kit; IQ Medical Ventures VB, Delft, the Netherlands). During the infusion of the foam, 2D TVU with the SonoAce X6 system was performed for assessment of proximal tubal occlusion ( Figure 2 ). Tubal patency was reported if leakage of the foam was visible into the fallopian tube past the microinsert and in the peritoneal cavity.
After HyFoSy, HSG was performed by another gynecologist with 6 years of experience. A No. 10 Foley catheter was used to infuse 20 mL of the iodine contrast material iopamidole (Iopamiro 370; Bracco SpA, Milan, Italy) into the uterine cavity. Digital images were recorded with a Zexira fluoroscopic system (Toshiba Medical Systems Europe BV, Zoetermeer, the Netherlands). The fallopian tubes were identified as patent or occluded by a single radiologist with 15 years of experience, who was blinded to the results of HyFoSy. No premedication was given to patients before HyFoSy and HSG.
The foam and the contrast medium were injected slowly and by repeated injections during HyFoSy and HSG to avoid false results due to tubal spasms. In fact, no tubal spasms were detected, as all occluded fallopian tubes continued to be occluded after repeated injections of the foam or the contrast medium, and all the patent fallopian tubes were readily identified at the first foam or contrast medium injection.
Patients with patent fallopian tubes on HSG were scheduled for additional HSG procedures at 3-month intervals until tubal occlusion was documented. After the confirmation of tubal occlusion at follow-up, patients were advised to discontinue other methods of contraception and to rely on Essure for birth control.
Statistical analyses were conducted with R version 3.2.0 software (http://www.r-project.org). Numerical variables were expressed as a mean and a range or as a median and an interquartile range. Attribute variables were expressed as numbers and percentages. In assessing the accuracy of the HyFoSy index test, we considered HSG to be the clinical reference standard. 21 The accuracy of HyFoSy was measured by the sum of the truepositive and true-negative results divided by the sum of the true-positive, true-negative, false-positive, and falsenegative results. The sensitivity, specificity, and positive and negative predictive values were calculated with their corresponding 95% confidence intervals (CIs). The differences in continuous data were tested for significance by the Wilcoxon signed rank test. P < .05 was considered statistically significant.
Results
Ninety patients with 178 fallopian tubes were enrolled in the study. Two of them had histories of unilateral salpingectomy. Eighty-six patients underwent the complete imaging protocol with 2D TVU, HyFoSy, and HSG. Of the other 4 patients, 1 had vasovagal syncope on HyFoSy; 1 refused HSG after HyFoSy; 1 had contrast medium leakage on HSG; and 1 withdrew her informed consent. These 4 patients were excluded from the analysis. Therefore, 86 patients with 170 fallopian tubes were included in the final study. Patients were 35 to 47 years old with a mean age of 40.1 years. The parity ranged from 0 to 4 with a mean of 1.9 births. Essure microinserts were successfully placed in all 170 fallopian tubes (100%). The mean number of microinsert coils remaining visible in the uterine cavity was 3.65 (range, 1-9), whereas the median of the visual analog scale pain score for Essure hysteroscopic sterilization was 2.7 (interquartile range, 2-3).
According to the protocol of our study, 2D TVU, HyFoSy, and HSG were scheduled 12 weeks after the procedure. Two-dimensional ultrasonography showed 151 of 170 (88.8%) microinserts in a satisfactory position and 19 of 170 (11.2%) in an unsatisfactory position. Hysterosalpingo-foam sonography showed 164 (96.5%) occluded and 6 (3.5%) patent fallopian tubes, whereas HSG showed 159 (93.5%) occluded and 11 (6.5%) patent fallopian tubes (Figure 3 ). The median visual analog scale pain scores were 0 (interquartile range, 0.0-3.0) for HyFoSy and 2.0 (interquartile range, 0.3-3.0) for HSG. The results indicated that the pain during HyFoSy was significantly lower compared to the pain during HSG (P 5 .005).
Of 159 occluded fallopian tubes on HSG, all of them were correctly identified by HyFoSy, resulting in sensitivity of 100% (95% CI, 97%-100%). Of 11 patent fallopian tubes on HSG, 6 were correctly identified with HyFoSy, resulting in specificity of 54.6% (95% CI, 23%-83%). When assessed as occluded on HyFoSy, the probability of an occluded fallopian tube represented the positive predictive value, whereas the probability of a patent fallopian tube, when assessed as patent on HyFoSy, represented the negative predictive value. The overall accuracy of HyFoSy was 97.1% (95% CI, 93%-99%; Table 1 ). No allergic reactions or long-term complications were reported for HyFoSy and HSG.
In the assessment of the secondary outcome, among 151 microinserts in a satisfactory position, 141 corresponding fallopian tubes were identified as occluded and 10 as patent, representing a positive predictive value of 93.4% (95% CI, 88%-97%). Among 19 microinserts in an unsatisfactory position, 1 tube was identified as patent and 18 as occluded, representing a negative predictive value of 5.2% (95% CI, 0%-26%). Of 159 occluded fallopian tubes on HSG, 141 had microinserts in a correct position on 2D TVU, resulting in sensitivity of 88.7% (95% CI, 83%-93%). Of 11 patent fallopian tubes on HSG, 1 had a microinsert in an incorrect position, with specificity of 9.1% (95% CI, 0%-41%). The concordance rate between a satisfactory microinsert position and tubal occlusion and an unsatisfactory position and tubal patency was 83.5% (95% CI, 77%-89%).
Of the 8 patients with patent fallopian tubes, 5 had 1 and 3 had both tubes patent. Due to a suspicion of microinsert migration, plain pelvic radiography was performed in 1 patient with a patent fallopian tube. However, the migration could not be excluded. Therefore, a laparoscopy was performed, during which the migration was not confirmed, and a salpingectomy was performed. The other 7 patients had additional HSG procedures at 3-month intervals until tubal occlusion was documented, which was achieved 6 months after Essure hysteroscopic sterilization in 4 patients and 9 months after the procedure in 3 patients. No pregnancy had been reported in the follow-up before April 2017. The results indicated that most of the patients in our study (85 of 86 [98.8%]) were able to rely on Essure for pregnancy prevention.
Discussion
Essure hysteroscopic sterilization is a permanent female contraception method that is very well tolerated, has a very high rate of success, and has a low rate of complications. 22 The efficacy of Essure sterilization needs to be verified by a confirmation test, HSG being the reference standard. Due to many disadvantages of HSG, there is a tendency to perform other imaging techniques. At the University Medical Center Maribor, the Dutch protocol is used to evaluate the efficacy of Essure hysteroscopic sterilization.
11 Two-dimensional TVU is performed as the first-line confirmation test after an uncomplicated bilateral sterilization procedure. The correct placement of microinserts on TVU was found to correlate well with tubal occlusion. When sterilization is complicated or performed unilaterally because of a history of salpingectomy, or when the confirmation with TVU is unsatisfactory, HSG is still indicated. Since the introduction of the Dutch protocol, the number of HSG procedures has reduced dramatically. Recently, HyFoSy was introduced as a possible alternative to HSG. 15, 18 It has been suggested to be an accurate test for evaluation of tubal patency in subfertile patients or evaluation of tubal occlusion after Essure placement for treatment of hydrosalpinges before in vitro fertilization. 15, [17] [18] [19] [20] 23 Recently, it has also been suggested to be an accurate test for the assessment of tubal blockage with the use of 3-dimensional TVU in a group of patients after Essure hysteroscopic sterilization or Essure placement in subfertile patients with hydrosalpinges. 24 It has been proven that HyFoSy has many advantages over HSG, as it is a nonionizing, less painful, and less time-consuming procedure and can be performed by a single gynecologist in the same ambulatory office as the TVU. Those factors could all contribute to an improvement in patient compliance.
To our knowledge, no study has compared HyFoSy with the use of 2D TVU to HSG in patients who had undergone Essure hysteroscopic sterilization solely for pregnancy prevention. In our study, all fallopian tubes found to be patent on HyFoSy were actually patent, as confirmed by HSG, which represented a negative predictive value of 100%. Of 164 occluded fallopian tubes on HyFoSy, 159 were actually occluded, as confirmed by HSG. There were 5 false-positive results, which represented specificity of 54.6% and a positive predictive value of 97.0%. Hysterosalpingo-foam sonography was found to be a less painful procedure than HSG, which is in line with the findings of other authors. 17, 20, 23, 24 Contrary to other findings, 17, 20, 24 the results of our study showed that the concordance rate for tubal occlusion between HyFoSy and HSG was not 100%. The number of patients included in our study was approximately twice as large as in other similar studies. However, only patients after Essure hysteroscopic sterilization were included, and HyFoSy was performed with the use of 2D TVU, as originally described by Emanuel and Exalto. 15 According to the results of our study, a patent fallopian tube on HyFoSy would not need a confirmation by HSG. However, patients with patent tubes cannot rely on Essure and are advised to have additional tubal patency testing at 3-month intervals until tubal occlusion is documented. Patients with occluded fallopian tubes on HyFoSy also cannot rely on Essure for pregnancy prevention. An occluded fallopian tube on HyFoSy should be confirmed by HSG. Therefore, HSG remains the reference standard for confirmation of tubal occlusion to ensure successful Essure hysteroscopic sterilization.
In contrast to the findings of some authors 9, 11 and in line with the findings of others, 24 the results of our study also show that microinserts in a satisfactory position do not correlate well with the tubal occlusion. However, it has been postulated that the absence of absolute physical occlusion of the tubes does not necessarily equate to failure of sterilization. 9, 11 Eventually, tubal occlusion was achieved on repeated HSG procedures in all of our patients with patent tubes on the first HSG, apart from 1, who underwent a laparoscopy and needed no further HSG control.
A limitation of our study was that it was not a randomized controlled study comparing HyFoSy to HSG. Another limitation was the lack of laparoscopic control with chromopertubation. Also, tubal spasms at HyFoSy and HSG could not be undoubtedly excluded; however, the contrast medium was injected slowly and with repeated injections to avoid them. The number of patients included in our study was small, resulting in wide confidence intervals, which limits the generalizability of the results. However, to preclude bias, all HyFoSy procedures were performed before HSG, so that the sonographer was blinded to the results of HSG during HyFoSy. Furthermore, the HSG results were interpreted by a radiologist, who was blinded to the results of HyFoSy.
